{"gene":"ALDH3A1","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":2003,"finding":"Recombinant human ALDH3A1 expressed in Sf9 insect cells demonstrates high substrate specificity for medium-chain (≥6 carbon) saturated and unsaturated aldehydes, including 4-hydroxy-2-nonenal (4-HNE); short-chain aldehydes (acetaldehyde, propionaldehyde, malondialdehyde) are very poor substrates. ALDH3A1 does not metabolize glucose-6-phosphate, 6-phosphoglucono-delta-lactone, or 6-phosphogluconate, ruling out roles in glycolysis or the pentose phosphate pathway. Immunohistochemistry localizes ALDH3A1 to corneal epithelial cells and stromal keratocytes, but not endothelial cells.","method":"Recombinant protein expression in Sf9 cells, affinity chromatography purification, enzyme kinetics (in vitro assay), immunohistochemistry with monoclonal antibodies","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro biochemical reconstitution with purified recombinant protein plus substrate specificity profiling and direct immunolocalization, multiple orthogonal methods in a single rigorous study","pmids":["12943535"],"is_preprint":false},{"year":2001,"finding":"Stable transfection of ALDH3A1 in V79 cells confers high-level protection against medium-chain aliphatic aldehydes (hexanal, trans-2-hexenal, trans-2-octenal, trans-2-nonenal, 4-HNE) by oxidizing the aldehyde moiety to a carboxyl group, preventing glutathione depletion, HNE-protein adduct formation, and apoptosis. ALDH1A1, by contrast, provides only moderate protection against trans-2-nonenal and none against the other medium-chain aldehydes. Neither isoform protects against acrolein, acetaldehyde, or chloroacetaldehyde.","method":"Stable transfection of V79 cells; cell viability, glutathione measurement, apoptosis assay, protein adduct detection; comparison of ALDH3A1 vs ALDH1A1 expressing lines","journal":"Chemico-biological interactions","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO/overexpression with defined cellular phenotypes, multiple orthogonal readouts (viability, GSH, apoptosis, adducts), replicated across two cell lines","pmids":["11306050"],"is_preprint":false},{"year":2003,"finding":"Stable transfection of human ALDH3A1 in human corneal epithelial (HCE) cells protects against UV- and 4-HNE-induced cytotoxicity and apoptosis. Apoptosis in mock-transfected cells occurs via caspase-3 activation and PARP cleavage; ALDH3A1-expressing cells are protected. ALDH3A1 increases NAD(P)H levels upon 4-HNE treatment (Km for 4-HNE = 54 µM) and prevents 4-HNE-protein adduct formation.","method":"Stable transfection in HCE cells; cell viability assay, DNA fragmentation, caspase-3 activation, PARP cleavage by Western blot, NAD(P)H fluorescence, protein adduct detection","journal":"Free radical biology & medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — defined cellular phenotype with loss-of-function/gain-of-function, multiple orthogonal mechanistic readouts, in vitro kinetics included","pmids":["12706498"],"is_preprint":false},{"year":2006,"finding":"Stable transfection of human ALDH3A1 in rabbit corneal fibroblasts (TRK43) protects against H2O2-, mitomycin C-, and etoposide-induced oxidative damage. ALDH3A1 prevents apoptosis, maintains reduced glutathione (GSH) levels and redox balance, and reduces 4-HNE-protein adduct accumulation. Carbonylation of ALDH3A1 itself occurs after oxidative treatment but does not significantly reduce its enzymatic activity.","method":"Stable transfection; cell viability, apoptosis assay, GSH measurement, Western blot for 4-HNE adducts, enzymatic activity assay","journal":"Free radical biology & medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean gain-of-function with multiple orthogonal cellular and biochemical readouts, replicated across multiple oxidative stressors","pmids":["17023273"],"is_preprint":false},{"year":2006,"finding":"ALDH3A1 protects other proteins from UV-induced inactivation through two mechanisms: (1) detoxification of reactive aldehydes (4-HNE, malondialdehyde) in the presence of NADP+, thereby protecting glucose-6-phosphate dehydrogenase (G6PDH) from aldehyde-mediated inactivation; and (2) direct UV-energy absorption, shielding other proteins from UVB damage through a competition mechanism. ALDH3A1 undergoes a structural transition at physiological temperatures suggestive of chaperone-like activity, though this transition alone does not account for protection.","method":"Co-incubation of purified ALDH3A1 with G6PDH under UVB and aldehyde stress; enzyme activity assays; spectroscopic studies of structural transitions","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified proteins, multiple mechanistic readouts, single lab but two distinct protective mechanisms validated biochemically","pmids":["17158879"],"is_preprint":false},{"year":2007,"finding":"Aldh3a1-null mice develop cataracts in anterior and posterior subcapsular regions and punctate cortical opacities by 1 month of age. Double knockout Aldh1a1/Aldh3a1 null mice show the same cataract phenotype with additive severity. Cataract formation is associated with decreased proteasomal activity, increased protein oxidation, increased GSH levels, and increased 4-HNE- and malondialdehyde-protein adducts. UVB exposure accelerates lens opacification, more pronounced in Aldh3a1-null than Aldh1a1-null mice. These data demonstrate that corneal ALDH3A1 and lens ALDH1A1 protect the eye against oxidative damage through both nonenzymatic (UV-light filtering) and enzymatic (aldehyde detoxification) functions.","method":"Knockout mouse model (single and double KO); ocular phenotyping, proteasome activity assay, oxidized protein measurement, 4-HNE/MDA adduct Western blot, UVB exposure challenge","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function in vivo with multiple biochemical phenotypic readouts, single/double KO epistasis, replicated across multiple timepoints and stressors","pmids":["17567582"],"is_preprint":false},{"year":2010,"finding":"UV-light causes non-native aggregation of ALDH3A1 via both covalent and non-covalent interactions, leading to loss of enzymatic activity. Spectroscopic analysis shows secondary and tertiary structure perturbation upon aggregation. MALDI-TOF mass spectrometry of LysC peptides reveals UV-induced chemical modifications to Trp, Met, and Cys residues, but the conserved active-site Cys remains intact after UV exposure that completely inactivates the enzyme, indicating that UV-induced inactivation results from aggregation/structural changes rather than direct active-site damage.","method":"UV irradiation of purified recombinant ALDH3A1; enzyme activity assay, spectroscopy (secondary/tertiary structure), MALDI-TOF mass spectrometry peptide mapping","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical reconstitution with purified protein, multiple orthogonal structural and chemical methods including mass spectrometry, single lab","pmids":["21203538"],"is_preprint":false},{"year":2012,"finding":"ALDH3A1 overexpression in rabbit corneal keratocytes (TRK43) protects cells from 4-HNE toxicity by: metabolizing 4-HNE and its glutathione conjugate, preventing 4-HNE-protein adduct formation, preventing apoptosis, maintaining glutathione homeostasis, and preserving proteasome function.","method":"Stable transfection; cell viability, morphology, Western blot for 4-HNE adducts, apoptosis assay, GSH measurement, proteasome activity assay","journal":"Free radical biology & medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean gain-of-function with six orthogonal cellular/biochemical readouts, single lab","pmids":["22406320"],"is_preprint":false},{"year":2014,"finding":"A selective submicromolar ALDH3A1 inhibitor, CB7 (1-[(4-fluorophenyl)sulfonyl]-2-methyl-1H-benzimidazole; IC50 0.2 µM), binds within the aldehyde substrate-binding pocket of ALDH3A1, as established by structural crystallography, kinetics, and mutagenesis. CB7 does not inhibit ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, or ALDH2. Sensitization of ALDH3A1-expressing lung adenocarcinoma (A549) and glioblastoma (SF767) cells to mafosfamide occurs in the presence of CB7, while primary lung fibroblasts lacking ALDH3A1 are unaffected.","method":"X-ray crystallography (structure of inhibitor-bound ALDH3A1), enzyme kinetics, site-directed mutagenesis, cell proliferation assay","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure, in vitro enzyme kinetics, mutagenesis, and cellular functional validation; multiple orthogonal methods in single rigorous study","pmids":["24387105"],"is_preprint":false},{"year":2014,"finding":"A selective ALDH3A1 inhibitor, CB29, binds within the aldehyde substrate-binding site of ALDH3A1 as shown by kinetics and crystallography, and enhances mafosfamide sensitivity in ALDH3A1-expressing A549 and SF767 tumor cells but not in ALDH3A1-negative CCD-13Lu fibroblasts. CB29 does not inhibit ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, or ALDH2 at up to 250 µM.","method":"X-ray crystallography, enzyme kinetics, cell proliferation assay","journal":"Chembiochem : a European journal of chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure of inhibitor-bound enzyme, kinetics, and cellular validation across matched ALDH3A1-positive and -negative lines; multiple orthogonal methods","pmids":["24677340"],"is_preprint":false},{"year":1999,"finding":"The Aldh3a1 gene is regulated by the aromatic hydrocarbon receptor (AhR): at least four functional aromatic hydrocarbon response elements (AHREs) in the 5' flanking region act cooperatively to mediate dioxin (TCDD)-induced upregulation. A putative negative regulatory element (NRE) controls basal expression independently of dioxin inducibility. TCDD-mediated upregulation in Hepa-1c1c7 cells depends exclusively on the AhR.","method":"Deletion reporter gene constructs (CAT/luciferase) transiently transfected in mouse hepatoma cells; genomic cloning and sequencing; AhR-dependence assessed with AhR-deficient mutant cells","journal":"Pharmacogenetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — promoter deletion/reporter assay with functional AhR requirement validation, multiple constructs, single lab","pmids":["10591537"],"is_preprint":false},{"year":1999,"finding":"The Aldh3a1c allele in SWR/J mice encodes a low-activity ALDH3A1 variant due to four amino acid substitutions (G88R, I154N, H305R, I352V). The I154N disrupts a potential alpha-helix in the Rossmann fold; H305R affects a beta-strand and likely directly impacts catalytic activity. Loss of ALDH3A1 activity in SWR/J mice is associated with extensive corneal clouding after UV exposure.","method":"RT-PCR and sequencing of cDNA; enzyme activity assay; comparison of allelic variants across inbred strains; UV challenge in vivo","journal":"Pharmacogenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — sequence-activity correlation with enzymatic validation, multiple strains, in vivo phenotype; single lab, no site-directed mutagenesis confirmation","pmids":["10376761"],"is_preprint":false},{"year":2003,"finding":"UVB radiation at ≥0.2 J/cm2 reduces corneal ALDH3A1 mRNA and protein levels (~80%) and enzymatic activity in C57BL/6J mice (transcriptional and/or post-translational downregulation). Lower doses (0.05–0.1 J/cm2) reduce enzymatic activity without altering mRNA or protein, indicating post-translational modification. In vitro experiments with purified recombinant ALDH3A1 show that UVR causes both covalent and non-covalent protein aggregation without detectable precipitation.","method":"Northern blot, Western blot, enzyme activity assay in mouse corneas; in vitro aggregation assay with purified recombinant ALDH3A1; dose-response UV exposure","journal":"Chemico-biological interactions","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo dose-response with multiple molecular readouts plus in vitro protein aggregation assay; single lab","pmids":["12604188"],"is_preprint":false},{"year":2015,"finding":"A small molecule, Alda-89, enables ALDH3A1 to metabolize acetaldehyde—a substrate it normally does not efficiently process. In vivo, Alda-89 combined with the ALDH2 activator Alda-1 reduces blood ethanol and acetaldehyde levels and decreases acetaldehyde-induced behavioral impairment in both wild-type and ALDH2*1/*2 heterozygous knock-in mice after acute ethanol intoxication.","method":"Pharmacological activation with small molecule (Alda-89); blood ethanol/acetaldehyde measurement; behavioral assay in wild-type and ALDH2*2 knock-in mice","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo pharmacological recruitment with biochemical (blood metabolite) and behavioral readouts, tested in two genotypes, published in PNAS","pmids":["25713355"],"is_preprint":false},{"year":2016,"finding":"ALDH3A1 decreases corneal epithelial cell proliferation through both enzymatic and non-enzymatic mechanisms. Inducible expression of wild-type (wt) but not catalytically-inactive (mu) ALDH3A1 promotes nuclear sequestration of tumor suppressor p53. In vivo, augmented proliferation is seen only in Aldh1a1/Aldh3a1 double-knockout mice (not Aldh3a1 single KO), and these hyper-proliferative corneas show near-complete loss of p53 expression. ALDH3A1 expression also modulates corneal differentiation markers.","method":"Tet-On inducible cell line expressing wt or catalytically-inactive ALDH3A1; BrdU proliferation assay; p53 nuclear localization by immunofluorescence; Aldh1a1/Aldh3a1 double-KO mouse cornea phenotyping; differentiation marker mRNA analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — catalytic mutant vs. wt comparison establishes enzymatic vs. non-enzymatic contributions, p53 localization mechanistically linked, validated in vivo with double-KO epistasis","pmids":["26751691"],"is_preprint":false},{"year":2017,"finding":"Recombinant human ALDH3A1 exhibits molecular chaperone-like activity in vitro, protecting SmaI restriction enzyme and citrate synthase from thermal stress-induced precipitation and inactivation. Overexpression of ALDH3A1 in E. coli confers resistance to thermal shock. ALDH3A1 overexpression in human corneal HCE-2 cells protects against H2O2- and tert-butyl hydroperoxide-induced cytotoxicity.","method":"In vitro chaperone assay with purified recombinant ALDH3A1 and model substrates (thermal aggregation assay); bacterial thermal shock survival; cell viability assay in HCE-2 cells","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro reconstitution of chaperone function with two model substrates plus cellular validation, single lab","pmids":["28526614"],"is_preprint":false},{"year":2018,"finding":"Activity-based protein profiling (chemoproteomics) identified the catalytic cysteine of ALDH3A1 as the primary cellular target of covalent ligand DKM 3-42, which impairs lung cancer cell survival. A more potent and selective lead covalent inhibitor EN40, identified through direct ALDH3A1-targeted chemoproteomic screening, inhibits ALDH3A1 activity and impairs lung cancer pathogenicity both in situ and in vivo.","method":"Activity-based protein profiling (ABPP); covalent ligand library screen; in vitro ALDH3A1 activity assay; lung cancer cell viability and tumor xenograft (in vivo)","journal":"ACS chemical biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — chemoproteomic target identification, enzymatic activity confirmation, in vitro and in vivo tumor models, multiple orthogonal methods","pmids":["30004670"],"is_preprint":false},{"year":2018,"finding":"Pharmacological inhibition of the Wnt pathway (porcupine inhibitor LGK974) synergistically suppresses glioma cell growth with temozolomide; transcriptomic analysis revealed ALDH3A1 expression is significantly downregulated by this combination. Knockdown of ALDH3A1 alone increases TMZ efficacy and reduces clonogenic potential, indicating that Wnt signaling-mediated chemoresistance is at least partly mediated through ALDH3A1.","method":"Porcupine inhibitor treatment, TMZ combination; transcriptomic analysis; ALDH3A1 siRNA knockdown; clonogenic assay; stem cell marker expression","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pathway epistasis by pharmacological inhibition and siRNA KD; single lab; no direct biochemical interaction assay","pmids":["29854309"],"is_preprint":false},{"year":2015,"finding":"FBXL12, an F-box protein forming an SCF ubiquitin E3 ligase, interacts specifically with members of the ALDH3 family and mediates their polyubiquitylation, leading to proteasomal degradation. FBXL12 deficiency causes ALDH3 accumulation in placenta and impairs trophoblast stem cell differentiation. Forced expression of ALDH3 in wild-type trophoblast stem cells phenocopies the FBXL12-deficient differentiation defect; inhibition of ALDH3 activity by gossypol rescues the phenotype of FBXL12 deficiency.","method":"Co-immunoprecipitation (FBXL12-ALDH3 interaction); polyubiquitylation assay; FBXL12 knockout mice; forced ALDH3 overexpression in TSCs; gossypol pharmacological rescue","journal":"Stem cells (Dayton, Ohio)","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ubiquitylation assay, KO mouse, gain-of-function rescue experiment, and pharmacological rescue; multiple orthogonal methods establishing mechanism","pmids":["26124079"],"is_preprint":false},{"year":2018,"finding":"Mutation of the circadian clock component Per2 in oncogene-transformed mouse embryonic fibroblasts leads to ~7-fold elevated ALDH3A1 protein levels compared to wild-type oncogene-transformed cells. Elevated ALDH3A1 prevents chemotherapeutic drug-induced accumulation of reactive oxygen species, conferring resistance to methotrexate, gemcitabine, etoposide, vincristine, and oxaliplatin. shRNA-mediated suppression of Aldh3a1 relieves this chemoresistance.","method":"Per2-mutant mouse embryonic fibroblasts; Western blot for ALDH3A1; ROS measurement; cell viability with chemotherapy agents; shRNA knockdown of Aldh3a1","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — genetic epistasis via KD rescue, ROS mechanistic readout, single lab; pathway placement via PER2/ALDH3A1 axis","pmids":["30429219"],"is_preprint":false},{"year":2006,"finding":"Arachidonic acid-induced growth suppression of A549 lung tumor cells is associated with reduced ALDH3A1 enzymatic activity, protein, and mRNA levels and increased lipid peroxidation. Activation of PPARγ mediates this downregulation; blockade of PPARγ with antagonist GW9662 prevents the arachidonic acid-mediated reduction of ALDH3A1 expression and the growth inhibition. PPARγ activation and ALDH3A1 reduction are also prevented by vitamin E co-treatment.","method":"Arachidonic acid treatment of A549 cells; PPARγ antagonist (GW9662) pharmacological blockade; vitamin E co-treatment; ALDH3A1 enzyme activity, protein, and mRNA measurement; NF-κB binding assay","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological epistasis (PPARγ blockade rescues ALDH3A1 expression); multiple corroborating readouts; single lab","pmids":["16716894"],"is_preprint":false},{"year":2020,"finding":"In aldh3a1-/- zebrafish larvae generated by CRISPR-Cas9, 4-HNE (but not methylglyoxal) accumulates, demonstrating that Aldh3a1 is the primary detoxifier of 4-HNE in vivo. 4-HNE accumulation disrupts pancreas morphology, impairs glucose homeostasis, and causes retinal vasodilatory alterations. The retinal and hyperglycemic phenotype can be rescued by L-Carnosine treatment.","method":"CRISPR-Cas9 knockout zebrafish; reactive carbonyl species measurement; glucose measurement; zebrafish transgenic reporter lines for vasculature and pancreas; transcriptomics; metabolomics; ALDH activity assay; pdx1 silencing epistasis","journal":"Redox biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function in vivo (CRISPR KO zebrafish), substrate identification by metabolomics, multiple phenotypic readouts, pharmacological rescue","pmids":["32980661"],"is_preprint":false},{"year":2023,"finding":"In NSCLC, hypoxia induces ALDH3A1 expression via the AHR/ARNT pathway; ALDH3A1 promotes cell proliferation by enhancing glycolysis and suppressing OXPHOS through activation of the HIF-1α/LDHA pathway. β-elemene downregulates ALDH3A1, inhibiting glycolysis and enhancing OXPHOS to suppress NSCLC proliferation in vitro and in vivo.","method":"Hypoxia cell treatment; ALDH3A1 knockdown/overexpression; glycolysis and OXPHOS measurement; HIF-1α/LDHA pathway Western blot; β-elemene treatment; xenograft mouse model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — cellular gain/loss-of-function with pathway marker readouts and in vivo xenograft; single lab; mechanism placement via HIF-1α/LDHA","pmids":["37730658"],"is_preprint":false},{"year":2025,"finding":"EN40 (covalent ALDH3A1 inhibitor targeting the catalytic cysteine) significantly enhances ferroptosis sensitivity in squamous cell carcinoma cells by its enzymatic activity-dependent inhibition of aldehyde catabolism and mitigation of lipid peroxidation. High ALDH3A1 expression in SCC is transcriptionally governed by TP63, which binds to a super-enhancer of ALDH3A1. The combination of EN40 and a ferroptosis inducer synergistically inhibits SCC proliferation in vitro and tumor growth in vivo.","method":"Covalent inhibitor (EN40) treatment; ferroptosis assay; lipid peroxidation measurement; ALDH3A1 overexpression/knockdown; ChIP-seq for TP63 binding to ALDH3A1 super-enhancer; SCC organoid and xenograft models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — enzymatic mechanism validated with covalent inhibitor and genetic controls, transcriptional regulation by TP63 via ChIP, multiple in vitro and in vivo models","pmids":["39863749"],"is_preprint":false},{"year":2024,"finding":"Mechanical strain (3%) applied to human keratocytes upregulates ALDH3A1 expression, which suppresses NF-κB nuclear translocation and reduces keratocyte proliferation and migration. ALDH3A1 knockdown promotes NF-κB nuclear translocation and enhances proliferation and migration. Elevated ALDH3A1 is also observed in mouse corneal injury models and in keratoconus patient keratocytes.","method":"Flexcell Tension System (3% strain); RT-qPCR and Western blot for ALDH3A1; RNAi knockdown; NF-κB nuclear translocation by immunofluorescence; BrdU proliferation and scratch wound healing assay; mouse injury model; single-cell RNA-seq of keratoconus patient keratocytes","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — KD with defined phenotypic readouts (proliferation, migration, NF-κB localization), in vivo confirmation, single lab","pmids":["39652089"],"is_preprint":false},{"year":1985,"finding":"Human ALDH3 (ALDH3A1) gene is assigned to chromosome 17 using human-rodent hybrid cells. The enzyme shows optimal activity with benzaldehyde and can utilize either NAD or NADP as cofactor. It is expressed at highest levels in lung and stomach, with no expression in fetal tissues, blood, hair roots, or fibroblasts.","method":"Human-rodent somatic cell hybrids; enzyme activity assay; antiserum immunoprecipitation; chromosome assignment","journal":"Annals of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chromosomal assignment by somatic cell hybrid panel, biochemical cofactor specificity by enzyme assay; foundational characterization study","pmids":["4073832"],"is_preprint":false},{"year":2025,"finding":"Bos taurus ALDH3A1 exhibits unprecedented turnover with the non-canonical redox cofactor nicotinamide mononucleotide (NMN+), with kcat values matching or exceeding that of NAD+. A conserved RH/QxxR sequence motif in ALDH3A1 reinforces cofactor positioning and pre-organizes the active site without dependence on the adenosine monophosphate moiety of NAD+. Structural and dynamic analyses support this mechanism.","method":"In vitro enzyme kinetics (NMN+ and NAD+ comparison); structural analysis; sequence motif analysis; introduction of RH/QxxR motif into other ALDH scaffolds","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution with kinetics and structural analysis; preprint, single lab, not yet peer-reviewed","pmids":["bio_10.1101_2025.08.01.668186"],"is_preprint":true},{"year":2026,"finding":"Dietary isothiocyanates (ITCs), specifically allyl-isothiocyanate, form a covalent adduct with the catalytic Cys243 residue of salivary ALDH3A1, causing irreversible inhibition. This inhibition, confirmed by X-ray crystallography and mass spectrometry, disrupts metabolic conversion of odorant aldehydes in saliva, modulating aroma release as confirmed by GC-MS.","method":"Enzymology (in vitro inhibition kinetics); X-ray crystallography of ITC-ALDH3A1 adduct; mass spectrometry; GC-MS analysis of odorant metabolites; ex vivo saliva assay","journal":"Food chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure identifying Cys243 as covalent adduct site, mass spectrometry confirmation, functional odorant release assay; multiple orthogonal methods, single lab","pmids":["41672019"],"is_preprint":false},{"year":2001,"finding":"ALDH3A1 expression is constitutively elevated in stable MCF-7 breast cancer sublines due to constitutively upregulated transcription driven by transactivated electrophile responsive elements (EpREs) in the 5'-upstream region of the ALDH3A1 gene. Elevated ALDH3A1 mRNA is not due to gene amplification, DNA hypomethylation, or mRNA stabilization, pointing to altered EpRE signaling as the mechanism.","method":"RT-PCR for ALDH3A1 mRNA; Southern blot for gene amplification; methylation analysis; mRNA stability assay; comparison of MCF-7 sublines selected with oxazaphosphorines or polycyclic aromatic hydrocarbons","journal":"Chemico-biological interactions","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — mechanistic exclusion of alternative mechanisms (amplification, methylation, mRNA stability) by direct assay; single lab; pathway placement via EpRE","pmids":["11306049"],"is_preprint":false}],"current_model":"ALDH3A1 is a cytosolic NAD(P)+-dependent aldehyde dehydrogenase that preferentially oxidizes medium-chain (≥6 carbon) aliphatic and hydroxy-alkenyl aldehydes, especially 4-hydroxy-2-nonenal (4-HNE) generated during lipid peroxidation, to their corresponding carboxylic acids; it is abundantly expressed in the mammalian cornea (where it functions as a 'corneal crystallin' protecting against UV-induced oxidative damage via aldehyde detoxification, NADPH generation, direct UV absorption, and chaperone-like protein protection), is inducibly regulated by the aryl hydrocarbon receptor (AhR) through aromatic hydrocarbon response elements and by NRF2/EpRE signaling, is targeted for proteasomal degradation by the SCF-FBXL12 E3 ligase (controlling trophoblast differentiation), harbors a catalytic Cys243 that is the target of covalent inhibitors and isothiocyanate adducts, modulates corneal epithelial homeostasis by promoting nuclear p53 sequestration to restrict proliferation, and confers cancer chemoresistance and ferroptosis resistance through enzymatic detoxification of toxic aldehydes including oxazaphosphorine metabolites, with transcription in squamous cancers governed by TP63 binding to a super-enhancer."},"narrative":{"mechanistic_narrative":"ALDH3A1 is a cytosolic NAD(P)+-dependent aldehyde dehydrogenase that detoxifies medium-chain (≥6 carbon) aliphatic and hydroxy-alkenyl aldehydes, most notably the lipid-peroxidation product 4-hydroxy-2-nonenal (4-HNE), oxidizing them to non-toxic carboxylic acids while short-chain aldehydes are poor substrates [PMID:12943535, PMID:11306050]. Through this activity it protects cells from oxidative and UV-induced injury: it prevents 4-HNE-protein adduct formation, preserves glutathione homeostasis and proteasome function, and blocks caspase-3/PARP-mediated apoptosis in corneal and other cells [PMID:12706498, PMID:17023273, PMID:22406320]. In vivo, Aldh3a1-null mice develop cataracts and accumulate 4-HNE/malondialdehyde adducts, and CRISPR knockout zebrafish establish ALDH3A1 as the primary 4-HNE detoxifier whose loss disrupts glucose homeostasis and ocular vasculature [PMID:17567582, PMID:32980661]. Beyond catalysis, the abundant corneal protein protects co-incubated enzymes by directly absorbing UV energy and exhibits molecular chaperone-like activity against thermal aggregation, acting as a multifunctional 'corneal crystallin' [PMID:17158879, PMID:28526614]. ALDH3A1 also restrains corneal epithelial proliferation through both enzymatic and non-enzymatic routes, promoting nuclear sequestration of p53 and suppressing NF-κB nuclear translocation [PMID:26751691, PMID:39652089]. Catalysis depends on an active-site Cys243 that is the covalent target of selective inhibitors and dietary isothiocyanate adducts, and selective substrate-pocket inhibitors (CB7, CB29, EN40) confirm a druggable aldehyde-binding site [PMID:24387105, PMID:24677340, PMID:30004670, PMID:41672019]. Expression is transcriptionally induced by the aryl hydrocarbon receptor via aromatic hydrocarbon response elements and by electrophile-responsive element signaling, and the SCF-FBXL12 E3 ligase targets ALDH3 proteins for proteasomal degradation to control trophoblast differentiation [PMID:10591537, PMID:11306049, PMID:26124079]. In cancer, ALDH3A1 confers chemoresistance and ferroptosis resistance by detoxifying toxic aldehydes and limiting lipid peroxidation, with high expression in squamous carcinoma driven by TP63 binding to a super-enhancer [PMID:30429219, PMID:39863749, PMID:30004670].","teleology":[{"year":1985,"claim":"Established the basic identity of the human enzyme—its chromosomal locus, dual NAD/NADP cofactor usage, and tissue distribution—providing the foundation for all later mechanistic work.","evidence":"Human-rodent somatic cell hybrids, enzyme activity assays, and antiserum immunoprecipitation","pmids":["4073832"],"confidence":"Medium","gaps":["Did not define physiological substrate preference","No structural or active-site information"]},{"year":1999,"claim":"Defined how ALDH3A1 transcription is controlled, showing the gene is an AhR target driven by cooperative aromatic hydrocarbon response elements and that natural low-activity alleles arise from coding substitutions affecting the Rossmann fold and catalysis.","evidence":"Promoter deletion/reporter assays in AhR-deficient hepatoma cells; allelic cDNA sequencing and enzyme activity across inbred mouse strains with UV challenge","pmids":["10591537","10376761"],"confidence":"Medium","gaps":["No site-directed mutagenesis confirmation of the allelic substitutions","Negative regulatory element factor not identified"]},{"year":2001,"claim":"Demonstrated the protective cellular function: ALDH3A1 oxidizes medium-chain aldehydes to confer resistance to aldehyde toxicity, distinguishing it from ALDH1A1, and linked its overexpression in cancer cells to EpRE-driven transcription.","evidence":"Stable transfection of V79 cells with viability/GSH/apoptosis/adduct readouts; RT-PCR and exclusion assays in MCF-7 oxazaphosphorine-resistant sublines","pmids":["11306050","11306049"],"confidence":"High","gaps":["EpRE transactivating factor not directly identified","Did not address in vivo relevance"]},{"year":2003,"claim":"Quantified substrate specificity with purified recombinant enzyme and localized ALDH3A1 to corneal epithelium and keratocytes, while showing it protects corneal cells against UV- and 4-HNE-induced apoptosis with measurable kinetics.","evidence":"Recombinant Sf9 protein with kinetics and immunohistochemistry; stable transfection of HCE cells with caspase-3/PARP/NAD(P)H readouts; mouse corneal UV dose-response","pmids":["12943535","12706498","12604188"],"confidence":"High","gaps":["UV downregulation mechanism (transcriptional vs post-translational) only partly resolved","No structural model of substrate binding"]},{"year":2006,"claim":"Revealed that ALDH3A1 is multifunctional—protecting other proteins both enzymatically (aldehyde clearance preserving G6PDH) and non-enzymatically by direct UV absorption—and that its downregulation by PPARγ underlies arachidonic-acid-induced tumor growth suppression.","evidence":"Co-incubation of purified ALDH3A1 with G6PDH under UVB/aldehyde stress; stable transfection of rabbit corneal fibroblasts; PPARγ antagonist epistasis in A549 cells","pmids":["17158879","17023273","16716894"],"confidence":"High","gaps":["Mechanism of the chaperone-like structural transition not defined","Direct PPARγ binding to the gene not shown"]},{"year":2007,"claim":"Provided in vivo genetic proof that corneal ALDH3A1 protects the eye against oxidative damage, with knockout mice developing cataracts and accumulating aldehyde-protein adducts, partly redundant with lens ALDH1A1.","evidence":"Single and double Aldh1a1/Aldh3a1 knockout mice with ocular phenotyping, proteasome and adduct assays, and UVB challenge","pmids":["17567582"],"confidence":"High","gaps":["Relative contribution of enzymatic vs UV-filtering function not separated genetically","Mechanism of cataractogenesis downstream of adducts unresolved"]},{"year":2010,"claim":"Showed that UV inactivation of ALDH3A1 results from aggregation and structural perturbation rather than direct active-site damage, since the catalytic cysteine remains intact in fully inactivated enzyme.","evidence":"UV irradiation of purified recombinant ALDH3A1 with activity assays, spectroscopy, and MALDI-TOF peptide mapping","pmids":["21203538"],"confidence":"High","gaps":["Aggregation interface not mapped","In vivo relevance of these specific modifications not tested"]},{"year":2012,"claim":"Consolidated the corneal protective mechanism, showing ALDH3A1 metabolizes 4-HNE and its glutathione conjugate while preserving proteasome function and GSH homeostasis.","evidence":"Stable transfection of rabbit keratocytes with six orthogonal cellular and biochemical readouts","pmids":["22406320"],"confidence":"High","gaps":["Single cell system","Did not address downstream signaling consequences"]},{"year":2014,"claim":"Defined a druggable aldehyde substrate-binding pocket by crystallizing selective small-molecule inhibitors (CB7, CB29) and validated that their inhibition sensitizes ALDH3A1-positive tumor cells to oxazaphosphorine chemotherapy.","evidence":"X-ray crystallography of inhibitor-bound ALDH3A1, enzyme kinetics, mutagenesis, and matched ALDH3A1-positive/negative cell proliferation assays","pmids":["24387105","24677340"],"confidence":"High","gaps":["Inhibitor potency in vivo not established in these studies","Selectivity against full ALDH family not exhaustively profiled"]},{"year":2015,"claim":"Demonstrated mechanistic plasticity—both substrate scope (small molecule Alda-89 enabling acetaldehyde metabolism in vivo) and a free-standing molecular chaperone activity protecting model substrates from thermal aggregation—and clarified its FBXL12-dependent turnover controlling trophoblast differentiation.","evidence":"Pharmacological activation with Alda-89 and blood metabolite/behavioral assays in mice; in vitro chaperone assays with citrate synthase/SmaI; reciprocal Co-IP, ubiquitylation assay, FBXL12 knockout mice, and gossypol rescue","pmids":["25713355","28526614","26124079"],"confidence":"High","gaps":["Structural basis of chaperone activity unresolved","FBXL12 specificity within ALDH3 family not fully dissected"]},{"year":2016,"claim":"Separated enzymatic from non-enzymatic roles in corneal homeostasis, showing only catalytically active ALDH3A1 drives nuclear p53 sequestration to restrict epithelial proliferation, validated by double-knockout epistasis.","evidence":"Tet-On inducible wt vs catalytically-inactive ALDH3A1 cells, BrdU and p53 immunofluorescence, and Aldh1a1/Aldh3a1 double-KO mouse cornea phenotyping","pmids":["26751691"],"confidence":"High","gaps":["Direct molecular link between catalysis and p53 trafficking not defined","Differentiation marker control mechanism unclear"]},{"year":2018,"claim":"Established ALDH3A1 as a cancer chemoresistance and survival factor across contexts—covalent active-site inhibition (DKM 3-42, EN40) impairs lung cancer pathogenicity, Wnt and PER2 circadian signaling converge on ALDH3A1 to drive resistance via ROS detoxification.","evidence":"Activity-based protein profiling and covalent inhibitors with lung cancer xenografts; porcupine inhibitor/TMZ epistasis with siRNA in glioma; Per2-mutant fibroblasts with shRNA and ROS readouts","pmids":["30004670","29854309","30429219"],"confidence":"High","gaps":["Direct regulatory links between Wnt/PER2 and the ALDH3A1 promoter not shown","Single-lab pathway placements"]},{"year":2020,"claim":"Confirmed in a third species (zebrafish) that ALDH3A1 is the principal in vivo 4-HNE detoxifier, with loss causing 4-HNE accumulation, hyperglycemia, and retinal vascular changes rescuable by L-carnosine.","evidence":"CRISPR-Cas9 knockout zebrafish with reactive carbonyl metabolomics, glucose measurement, transgenic vascular/pancreas reporters, and pharmacological rescue","pmids":["32980661"],"confidence":"High","gaps":["Mechanism linking 4-HNE to pancreatic/retinal phenotypes not fully resolved","Mammalian metabolic relevance inferred not demonstrated"]},{"year":2023,"claim":"Extended the cancer role to metabolic reprogramming, showing hypoxia-induced ALDH3A1 (via AHR/ARNT) promotes glycolysis and suppresses OXPHOS through the HIF-1α/LDHA axis to drive NSCLC proliferation.","evidence":"Hypoxia treatment, ALDH3A1 knockdown/overexpression, glycolysis/OXPHOS assays, pathway Western blots, and xenografts","pmids":["37730658"],"confidence":"Medium","gaps":["Direct mechanism linking aldehyde dehydrogenase activity to HIF-1α/LDHA not established","Single-lab pathway placement"]},{"year":2025,"claim":"Defined the transcriptional control and therapeutic exploitation of ALDH3A1 in squamous carcinoma—TP63 drives high expression via a super-enhancer, and covalent inhibition (EN40) enzyme-dependently sensitizes cells to ferroptosis—and uncovered a Cys243-targeting dietary isothiocyanate adduct modulating odorant aldehyde metabolism, plus non-canonical NMN+ cofactor usage.","evidence":"ChIP-seq of TP63, covalent EN40 with ferroptosis/lipid peroxidation assays and SCC organoids/xenografts; crystallography and mass spectrometry of ITC-Cys243 adducts with GC-MS; in vitro kinetics with NMN+ (preprint)","pmids":["39863749","41672019","bio_10.1101_2025.08.01.668186"],"confidence":"High","gaps":["Physiological significance of NMN+ cofactor usage not established (preprint)","Generality of TP63 regulation across SCC subtypes not fully tested"]},{"year":null,"claim":"How the non-enzymatic functions (UV absorption, chaperone activity, p53 sequestration) are mechanistically coordinated with catalytic aldehyde clearance, and whether targeting ALDH3A1 in cancer can be achieved without compromising its protective corneal/ocular roles, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model linking catalysis to chaperone/UV-filtering functions","Tissue-selective therapeutic window not defined","Direct molecular partners mediating p53 and NF-κB effects unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,2,21,25]},{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[4,15]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[2,3,5,21]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,21]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[16,19,23]}],"complexes":[],"partners":["FBXL12","TP63","P53"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P30838","full_name":"Aldehyde dehydrogenase, dimeric NADP-preferring","aliases":["ALDHIII","Aldehyde dehydrogenase 3","Aldehyde dehydrogenase family 3 member A1"],"length_aa":453,"mass_kda":50.4,"function":"ALDHs play a major role in the detoxification of alcohol-derived acetaldehyde (Probable). They are involved in the metabolism of corticosteroids, biogenic amines, neurotransmitters, and lipid peroxidation (Probable). Oxidizes medium and long chain aldehydes into non-toxic fatty acids (PubMed:1737758). Preferentially oxidizes aromatic aldehyde substrates (PubMed:1737758). Comprises about 50 percent of corneal epithelial soluble proteins (By similarity). May play a role in preventing corneal damage caused by ultraviolet light (By similarity)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P30838/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ALDH3A1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ALDH3A1","total_profiled":1310},"omim":[{"mim_id":"100660","title":"ALDEHYDE DEHYDROGENASE, FAMILY 3, SUBFAMILY A, MEMBER 1; ALDH3A1","url":"https://www.omim.org/entry/100660"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":504.2},{"tissue":"salivary gland","ntpm":117.1},{"tissue":"stomach 1","ntpm":212.1}],"url":"https://www.proteinatlas.org/search/ALDH3A1"},"hgnc":{"alias_symbol":[],"prev_symbol":["ALDH3"]},"alphafold":{"accession":"P30838","domains":[{"cath_id":"3.40.605.10","chopping":"4-212_410-430","consensus_level":"high","plddt":98.6847,"start":4,"end":430},{"cath_id":"3.40.309.10","chopping":"217-396","consensus_level":"high","plddt":98.6819,"start":217,"end":396}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P30838","model_url":"https://alphafold.ebi.ac.uk/files/AF-P30838-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P30838-F1-predicted_aligned_error_v6.png","plddt_mean":97.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ALDH3A1","jax_strain_url":"https://www.jax.org/strain/search?query=ALDH3A1"},"sequence":{"accession":"P30838","fasta_url":"https://rest.uniprot.org/uniprotkb/P30838.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P30838/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P30838"}},"corpus_meta":[{"pmid":"17920722","id":"PMC_17920722","title":"ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors.","date":"2007","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/17920722","citation_count":172,"is_preprint":false},{"pmid":"11914911","id":"PMC_11914911","title":"Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens.","date":"2002","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11914911","citation_count":164,"is_preprint":false},{"pmid":"17567582","id":"PMC_17567582","title":"Multiple and additive functions of ALDH3A1 and ALDH1A1: cataract phenotype and ocular oxidative damage in Aldh3a1(-/-)/Aldh1a1(-/-) knock-out mice.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17567582","citation_count":156,"is_preprint":false},{"pmid":"12943535","id":"PMC_12943535","title":"Human aldehyde dehydrogenase 3A1 (ALDH3A1): biochemical characterization and immunohistochemical localization in the cornea.","date":"2003","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12943535","citation_count":138,"is_preprint":false},{"pmid":"16797007","id":"PMC_16797007","title":"ALDH3A1: a corneal crystallin with diverse functions.","date":"2006","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/16797007","citation_count":121,"is_preprint":false},{"pmid":"18496131","id":"PMC_18496131","title":"Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.","date":"2008","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/18496131","citation_count":109,"is_preprint":false},{"pmid":"12706498","id":"PMC_12706498","title":"Aldh3a1 protects human corneal epithelial cells from ultraviolet- and 4-hydroxy-2-nonenal-induced oxidative damage.","date":"2003","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12706498","citation_count":101,"is_preprint":false},{"pmid":"11306050","id":"PMC_11306050","title":"Selective protection by stably transfected human ALDH3A1 (but not human ALDH1A1) against toxicity of aliphatic aldehydes in V79 cells.","date":"2001","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/11306050","citation_count":73,"is_preprint":false},{"pmid":"30333913","id":"PMC_30333913","title":"Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/30333913","citation_count":70,"is_preprint":false},{"pmid":"28671577","id":"PMC_28671577","title":"Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells.","date":"2017","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/28671577","citation_count":65,"is_preprint":false},{"pmid":"24387105","id":"PMC_24387105","title":"Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24387105","citation_count":62,"is_preprint":false},{"pmid":"4073832","id":"PMC_4073832","title":"Chromosome assignment, biochemical and immunological studies on a human aldehyde dehydrogenase, ALDH3.","date":"1985","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/4073832","citation_count":58,"is_preprint":false},{"pmid":"32297178","id":"PMC_32297178","title":"Exosomes carrying ALDOA and ALDH3A1 from irradiated lung cancer cells enhance migration and invasion of recipients by accelerating glycolysis.","date":"2020","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32297178","citation_count":56,"is_preprint":false},{"pmid":"17023273","id":"PMC_17023273","title":"Antioxidant function of corneal ALDH3A1 in cultured stromal fibroblasts.","date":"2006","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17023273","citation_count":56,"is_preprint":false},{"pmid":"29854309","id":"PMC_29854309","title":"Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma in vitro.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29854309","citation_count":52,"is_preprint":false},{"pmid":"25713355","id":"PMC_25713355","title":"Pharmacological recruitment of aldehyde dehydrogenase 3A1 (ALDH3A1) to assist ALDH2 in acetaldehyde and ethanol metabolism in vivo.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25713355","citation_count":52,"is_preprint":false},{"pmid":"17158879","id":"PMC_17158879","title":"Mechanisms involved in the protection of UV-induced protein inactivation by the corneal crystallin ALDH3A1.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17158879","citation_count":51,"is_preprint":false},{"pmid":"24677340","id":"PMC_24677340","title":"Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity.","date":"2014","source":"Chembiochem : a European journal of chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/24677340","citation_count":50,"is_preprint":false},{"pmid":"37730658","id":"PMC_37730658","title":"Hypoxia-induced ALDH3A1 promotes the proliferation of non-small-cell lung cancer by regulating energy metabolism reprogramming.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37730658","citation_count":48,"is_preprint":false},{"pmid":"31817719","id":"PMC_31817719","title":"ALDH3A1 Overexpression in Melanoma and Lung Tumors Drives Cancer Stem Cell Expansion, Impairing Immune Surveillance through Enhanced PD-L1 Output.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31817719","citation_count":48,"is_preprint":false},{"pmid":"16716894","id":"PMC_16716894","title":"Arachidonic acid suppresses growth of human lung tumor A549 cells through down-regulation of ALDH3A1 expression.","date":"2006","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16716894","citation_count":47,"is_preprint":false},{"pmid":"32980661","id":"PMC_32980661","title":"Elevated 4-hydroxynonenal induces hyperglycaemia via Aldh3a1 loss in zebrafish and associates with diabetes progression in humans.","date":"2020","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/32980661","citation_count":46,"is_preprint":false},{"pmid":"22406320","id":"PMC_22406320","title":"Molecular mechanisms of ALDH3A1-mediated cellular protection against 4-hydroxy-2-nonenal.","date":"2012","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22406320","citation_count":45,"is_preprint":false},{"pmid":"30004670","id":"PMC_30004670","title":"Chemoproteomics-Enabled Covalent Ligand Screening Reveals ALDH3A1 as a Lung Cancer Therapy Target.","date":"2018","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30004670","citation_count":42,"is_preprint":false},{"pmid":"10591537","id":"PMC_10591537","title":"Mouse cytosolic class 3 aldehyde dehydrogenase (Aldh3a1): gene structure and regulation of constitutive and dioxin-inducible expression.","date":"1999","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10591537","citation_count":38,"is_preprint":false},{"pmid":"12604188","id":"PMC_12604188","title":"Ultraviolet radiation decreases expression and induces aggregation of corneal ALDH3A1.","date":"2003","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/12604188","citation_count":36,"is_preprint":false},{"pmid":"8363638","id":"PMC_8363638","title":"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induced ethoxyresorufin-O-deethylase (EROD) and aldehyde dehydrogenase (ALDH3) activities in the brain and liver. A comparison between the most TCDD-susceptible and the most TCDD-resistant rat strain.","date":"1993","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8363638","citation_count":34,"is_preprint":false},{"pmid":"23451057","id":"PMC_23451057","title":"Efficient E. coli expression strategies for production of soluble human crystallin ALDH3A1.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23451057","citation_count":31,"is_preprint":false},{"pmid":"21203538","id":"PMC_21203538","title":"Structural and functional modifications of corneal crystallin ALDH3A1 by UVB light.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21203538","citation_count":27,"is_preprint":false},{"pmid":"8607142","id":"PMC_8607142","title":"Induction of CYP1A1 and ALDH-3 in lymphoid tissues from Fisher 344 rats exposed to 2,3,7,8-tetrachlorodibenzodioxin (TCDD).","date":"1996","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8607142","citation_count":27,"is_preprint":false},{"pmid":"26751691","id":"PMC_26751691","title":"ALDH3A1 Plays a Functional Role in Maintenance of Corneal Epithelial Homeostasis.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26751691","citation_count":24,"is_preprint":false},{"pmid":"30429219","id":"PMC_30429219","title":"Mutation of the gene encoding the circadian clock component PERIOD2 in oncogenic cells confers chemoresistance by up-regulating the Aldh3a1 gene.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30429219","citation_count":24,"is_preprint":false},{"pmid":"24276407","id":"PMC_24276407","title":"ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ß-catenin pathway.","date":"2013","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24276407","citation_count":24,"is_preprint":false},{"pmid":"33294267","id":"PMC_33294267","title":"Shikonin enhances the antitumor effect of cabazitaxel in prostate cancer stem cells and reverses cabazitaxel resistance by inhibiting ABCG2 and ALDH3A1.","date":"2020","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33294267","citation_count":23,"is_preprint":false},{"pmid":"10376761","id":"PMC_10376761","title":"Four amino acid changes are associated with the Aldh3a1 locus polymorphism in mice which may be responsible for corneal sensitivity to ultraviolet light.","date":"1999","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10376761","citation_count":23,"is_preprint":false},{"pmid":"34234849","id":"PMC_34234849","title":"ALDH3A1 driving tumor metastasis is mediated by p53/BAG1 in lung adenocarcinoma.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34234849","citation_count":18,"is_preprint":false},{"pmid":"11306049","id":"PMC_11306049","title":"Three different stable human breast adenocarcinoma sublines that overexpress ALDH3A1 and certain other enzymes, apparently as a consequence of constitutively upregulated gene transcription mediated by transactivated EpREs (electrophile responsive elements) present in the 5'-upstream regions of these genes.","date":"2001","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/11306049","citation_count":18,"is_preprint":false},{"pmid":"26124079","id":"PMC_26124079","title":"FBXL12-Mediated Degradation of ALDH3 is Essential for Trophoblast Differentiation During Placental Development.","date":"2015","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/26124079","citation_count":16,"is_preprint":false},{"pmid":"28526614","id":"PMC_28526614","title":"Human aldehyde dehydrogenase 3A1 (ALDH3A1) exhibits chaperone-like function.","date":"2017","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28526614","citation_count":16,"is_preprint":false},{"pmid":"8979087","id":"PMC_8979087","title":"The human aldehyde dehydrogenase 3 gene (ALDH3): identification of a new exon and diverse mRNA isoforms, and functional analysis of the promoter.","date":"1996","source":"Gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/8979087","citation_count":16,"is_preprint":false},{"pmid":"35188323","id":"PMC_35188323","title":"ALDH3A1 overexpression in OSCC inhibits inflammation via phospho-Ser727 at STAT3 in tumor-associated macrophages.","date":"2022","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35188323","citation_count":15,"is_preprint":false},{"pmid":"15547490","id":"PMC_15547490","title":"Alkali burn causes aldehyde dehydrogenase 3A1 (ALDH3A1) decrease in mouse cornea.","date":"2004","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/15547490","citation_count":15,"is_preprint":false},{"pmid":"21296057","id":"PMC_21296057","title":"Comparative studies of vertebrate aldehyde dehydrogenase 3: sequences, structures, phylogeny and evolution. Evidence for a mammalian origin for the ALDH3A1 gene.","date":"2011","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/21296057","citation_count":15,"is_preprint":false},{"pmid":"28038895","id":"PMC_28038895","title":"Corneal haze phenotype in Aldh3a1-null mice: In vivo confocal microscopy and tissue imaging mass spectrometry.","date":"2016","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/28038895","citation_count":15,"is_preprint":false},{"pmid":"21251908","id":"PMC_21251908","title":"Importance of inverse correlation between ALDH3A1 and PPARγ in tumor cells and tissue regeneration.","date":"2011","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/21251908","citation_count":13,"is_preprint":false},{"pmid":"8761421","id":"PMC_8761421","title":"Hepatocyte expression of tumor associated aldehyde dehydrogenase (ALDH-3) and p21 Ras following diethylnitrosamine (DEN) initiation and chronic exposure to di(2-ethylhexyl)phthalate (DHEP).","date":"1996","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/8761421","citation_count":13,"is_preprint":false},{"pmid":"11121727","id":"PMC_11121727","title":"Changes of CYP1A1, GST, and ALDH3 enzymes in hepatoma cell lines undergoing enhanced lipid peroxidation.","date":"2000","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11121727","citation_count":12,"is_preprint":false},{"pmid":"1859355","id":"PMC_1859355","title":"Aldehyde dehydrogenase (ALDH) isozymes in the gray short-tailed opossum (Monodelphis domestica): tissue and subcellular distribution and biochemical genetics of ALDH3.","date":"1991","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1859355","citation_count":12,"is_preprint":false},{"pmid":"12604189","id":"PMC_12604189","title":"Acute-phase response to benzo[a]pyrene and induction of rat ALDH3A1.","date":"2003","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/12604189","citation_count":12,"is_preprint":false},{"pmid":"27976863","id":"PMC_27976863","title":"Development of Highly Selective Fluorescent Probe Enabling Flow-Cytometric Isolation of ALDH3A1-Positive Viable Cells.","date":"2016","source":"Bioconjugate chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27976863","citation_count":11,"is_preprint":false},{"pmid":"38225738","id":"PMC_38225738","title":"ALDH3A1 upregulation inhibits neutrophils N2 polarization and halts oral cancer growth.","date":"2024","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/38225738","citation_count":10,"is_preprint":false},{"pmid":"17151192","id":"PMC_17151192","title":"Constitutive and 3-methylcholanthrene-induced rat ALDH3A1 expression is mediated by multiple xenobiotic response elements.","date":"2006","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/17151192","citation_count":10,"is_preprint":false},{"pmid":"12604185","id":"PMC_12604185","title":"An algorithm for identification and ranking of family-specific residues, applied to the ALDH3 family.","date":"2003","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/12604185","citation_count":10,"is_preprint":false},{"pmid":"33596621","id":"PMC_33596621","title":"Association with Corneal Remodeling Related Genes, ALDH3A1, LOX, and SPARC Genes Variations in Korean Keratoconus Patients.","date":"2021","source":"Korean journal of ophthalmology : KJO","url":"https://pubmed.ncbi.nlm.nih.gov/33596621","citation_count":8,"is_preprint":false},{"pmid":"39863749","id":"PMC_39863749","title":"Targeting aldehyde dehydrogenase ALDH3A1 increases ferroptosis vulnerability in squamous cancer.","date":"2025","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39863749","citation_count":6,"is_preprint":false},{"pmid":"35011749","id":"PMC_35011749","title":"Common ALDH3A1 Gene Variant Associated with Keratoconus Risk in the Polish Population.","date":"2021","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35011749","citation_count":5,"is_preprint":false},{"pmid":"11306038","id":"PMC_11306038","title":"Inhibition of ALDH3A1-catalyzed oxidation by chlorpropamide analogues.","date":"2001","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/11306038","citation_count":5,"is_preprint":false},{"pmid":"19894643","id":"PMC_19894643","title":"The oxidation status of ALDH3A1 in human saliva and its correlation with antioxidant capacity measured by ORAC method.","date":"2009","source":"Acta poloniae pharmaceutica","url":"https://pubmed.ncbi.nlm.nih.gov/19894643","citation_count":5,"is_preprint":false},{"pmid":"39652089","id":"PMC_39652089","title":"Corneal strain influences keratocyte proliferation and migration through upregulation of ALDH3A1 expression.","date":"2024","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/39652089","citation_count":4,"is_preprint":false},{"pmid":"37021113","id":"PMC_37021113","title":"Identification of a peptide ligand for human ALDH3A1 through peptide phage display: Prediction and characterization of protein interaction sites and inhibition of ALDH3A1 enzymatic activity.","date":"2023","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/37021113","citation_count":4,"is_preprint":false},{"pmid":"32493941","id":"PMC_32493941","title":"Generation and characterization of Aldh3-Cre transgenic mice as a tool for conditional gene deletion in postnatal cornea.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32493941","citation_count":4,"is_preprint":false},{"pmid":"38191346","id":"PMC_38191346","title":"Chronic restraint stress promotes oral squamous cell carcinoma development by inhibiting ALDH3A1 via stress response hormone.","date":"2024","source":"BMC oral health","url":"https://pubmed.ncbi.nlm.nih.gov/38191346","citation_count":4,"is_preprint":false},{"pmid":"11672702","id":"PMC_11672702","title":"Inhibition of ALDH3A1-catalyzed oxidation by chlorpropamide analogues.","date":"2001","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/11672702","citation_count":4,"is_preprint":false},{"pmid":"11306048","id":"PMC_11306048","title":"Effects of 3-methylcholanthrene and aspirin co-administration on ALDH3A1 in HepG2 cells.","date":"2001","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/11306048","citation_count":4,"is_preprint":false},{"pmid":"41327788","id":"PMC_41327788","title":"Multi-omics revealed GOT1/ALDH3A1 pathway attenuated head and neck squamous cell carcinoma and increased cisplatin sensitivity through ROS induced by mitochondrial dysfunction.","date":"2025","source":"Redox report : communications in free radical research","url":"https://pubmed.ncbi.nlm.nih.gov/41327788","citation_count":1,"is_preprint":false},{"pmid":"41046948","id":"PMC_41046948","title":"Aldehyde dehydrogenase ALDH3A1 rescues cigarette smoke-induced emphysema by conferring alveolar type 2 to type 1 cell transition.","date":"2025","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41046948","citation_count":1,"is_preprint":false},{"pmid":"41564796","id":"PMC_41564796","title":"A viral-host redox axis: EBNA1-FOSL2-ALDH3A1 defines a targetable vulnerability in EBV-positive carcinomas.","date":"2026","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/41564796","citation_count":1,"is_preprint":false},{"pmid":"40657474","id":"PMC_40657474","title":"Association of ALDH3A1 expression with tumor differentiation, pathological stage, and nodal status in oral squamous cell carcinoma.","date":"2025","source":"Journal of Taibah University Medical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40657474","citation_count":1,"is_preprint":false},{"pmid":"41513604","id":"PMC_41513604","title":"ALDH3A1-dependent Nrf2/HO-1/GPX4 pathway supports AHR as a promising therapeutic target for ferroptosis and promotes imperatorin-mediated lung protection.","date":"2026","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/41513604","citation_count":0,"is_preprint":false},{"pmid":"41831802","id":"PMC_41831802","title":"Aldh3a1-mediated detoxification of reactive aldehydes contributes to distinct muscle responses to amyotrophic lateral sclerosis progression.","date":"2026","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41831802","citation_count":0,"is_preprint":false},{"pmid":"39677625","id":"PMC_39677625","title":"ALDH3A1-mediated detoxification of reactive aldehydes contributes to distinct muscle responses to denervation and Amyotrophic Lateral Sclerosis progression.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39677625","citation_count":0,"is_preprint":false},{"pmid":"40825534","id":"PMC_40825534","title":"Sad from Proteobacteria is a Structurally Distinct ALDH3 Enzyme Specialized for the Oxidation of Steroidal Aldehydes.","date":"2025","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40825534","citation_count":0,"is_preprint":false},{"pmid":"41672019","id":"PMC_41672019","title":"Dietary isothiocyanates inhibit the oxidative activity of salivary aldehyde dehydrogenase ALDH3A1 and modulate aroma release.","date":"2026","source":"Food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41672019","citation_count":0,"is_preprint":false},{"pmid":"41724003","id":"PMC_41724003","title":"Novel benzophenones from the fibrous roots of Anemarrhena asphodeloides Bunge inhibit hepatocellular carcinoma activity by targeting ALDH3A1.","date":"2026","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41724003","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.13.688345","title":"Genotoxic formaldehyde and lipid aldehydes are sources of DNA damage in keratinocytes","date":"2025-11-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.13.688345","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.01.668186","title":"A Sequence Motif Enables Widespread Use of Non-Canonical Redox Cofactors in Natural Enzymes","date":"2025-08-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.01.668186","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43887,"output_tokens":9078,"usd":0.133915,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19164,"output_tokens":5562,"usd":0.117435,"stage2_stop_reason":"end_turn"},"total_usd":0.25135,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"Recombinant human ALDH3A1 expressed in Sf9 insect cells demonstrates high substrate specificity for medium-chain (≥6 carbon) saturated and unsaturated aldehydes, including 4-hydroxy-2-nonenal (4-HNE); short-chain aldehydes (acetaldehyde, propionaldehyde, malondialdehyde) are very poor substrates. ALDH3A1 does not metabolize glucose-6-phosphate, 6-phosphoglucono-delta-lactone, or 6-phosphogluconate, ruling out roles in glycolysis or the pentose phosphate pathway. Immunohistochemistry localizes ALDH3A1 to corneal epithelial cells and stromal keratocytes, but not endothelial cells.\",\n      \"method\": \"Recombinant protein expression in Sf9 cells, affinity chromatography purification, enzyme kinetics (in vitro assay), immunohistochemistry with monoclonal antibodies\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro biochemical reconstitution with purified recombinant protein plus substrate specificity profiling and direct immunolocalization, multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"12943535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Stable transfection of ALDH3A1 in V79 cells confers high-level protection against medium-chain aliphatic aldehydes (hexanal, trans-2-hexenal, trans-2-octenal, trans-2-nonenal, 4-HNE) by oxidizing the aldehyde moiety to a carboxyl group, preventing glutathione depletion, HNE-protein adduct formation, and apoptosis. ALDH1A1, by contrast, provides only moderate protection against trans-2-nonenal and none against the other medium-chain aldehydes. Neither isoform protects against acrolein, acetaldehyde, or chloroacetaldehyde.\",\n      \"method\": \"Stable transfection of V79 cells; cell viability, glutathione measurement, apoptosis assay, protein adduct detection; comparison of ALDH3A1 vs ALDH1A1 expressing lines\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO/overexpression with defined cellular phenotypes, multiple orthogonal readouts (viability, GSH, apoptosis, adducts), replicated across two cell lines\",\n      \"pmids\": [\"11306050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Stable transfection of human ALDH3A1 in human corneal epithelial (HCE) cells protects against UV- and 4-HNE-induced cytotoxicity and apoptosis. Apoptosis in mock-transfected cells occurs via caspase-3 activation and PARP cleavage; ALDH3A1-expressing cells are protected. ALDH3A1 increases NAD(P)H levels upon 4-HNE treatment (Km for 4-HNE = 54 µM) and prevents 4-HNE-protein adduct formation.\",\n      \"method\": \"Stable transfection in HCE cells; cell viability assay, DNA fragmentation, caspase-3 activation, PARP cleavage by Western blot, NAD(P)H fluorescence, protein adduct detection\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — defined cellular phenotype with loss-of-function/gain-of-function, multiple orthogonal mechanistic readouts, in vitro kinetics included\",\n      \"pmids\": [\"12706498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Stable transfection of human ALDH3A1 in rabbit corneal fibroblasts (TRK43) protects against H2O2-, mitomycin C-, and etoposide-induced oxidative damage. ALDH3A1 prevents apoptosis, maintains reduced glutathione (GSH) levels and redox balance, and reduces 4-HNE-protein adduct accumulation. Carbonylation of ALDH3A1 itself occurs after oxidative treatment but does not significantly reduce its enzymatic activity.\",\n      \"method\": \"Stable transfection; cell viability, apoptosis assay, GSH measurement, Western blot for 4-HNE adducts, enzymatic activity assay\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean gain-of-function with multiple orthogonal cellular and biochemical readouts, replicated across multiple oxidative stressors\",\n      \"pmids\": [\"17023273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ALDH3A1 protects other proteins from UV-induced inactivation through two mechanisms: (1) detoxification of reactive aldehydes (4-HNE, malondialdehyde) in the presence of NADP+, thereby protecting glucose-6-phosphate dehydrogenase (G6PDH) from aldehyde-mediated inactivation; and (2) direct UV-energy absorption, shielding other proteins from UVB damage through a competition mechanism. ALDH3A1 undergoes a structural transition at physiological temperatures suggestive of chaperone-like activity, though this transition alone does not account for protection.\",\n      \"method\": \"Co-incubation of purified ALDH3A1 with G6PDH under UVB and aldehyde stress; enzyme activity assays; spectroscopic studies of structural transitions\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified proteins, multiple mechanistic readouts, single lab but two distinct protective mechanisms validated biochemically\",\n      \"pmids\": [\"17158879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Aldh3a1-null mice develop cataracts in anterior and posterior subcapsular regions and punctate cortical opacities by 1 month of age. Double knockout Aldh1a1/Aldh3a1 null mice show the same cataract phenotype with additive severity. Cataract formation is associated with decreased proteasomal activity, increased protein oxidation, increased GSH levels, and increased 4-HNE- and malondialdehyde-protein adducts. UVB exposure accelerates lens opacification, more pronounced in Aldh3a1-null than Aldh1a1-null mice. These data demonstrate that corneal ALDH3A1 and lens ALDH1A1 protect the eye against oxidative damage through both nonenzymatic (UV-light filtering) and enzymatic (aldehyde detoxification) functions.\",\n      \"method\": \"Knockout mouse model (single and double KO); ocular phenotyping, proteasome activity assay, oxidized protein measurement, 4-HNE/MDA adduct Western blot, UVB exposure challenge\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function in vivo with multiple biochemical phenotypic readouts, single/double KO epistasis, replicated across multiple timepoints and stressors\",\n      \"pmids\": [\"17567582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"UV-light causes non-native aggregation of ALDH3A1 via both covalent and non-covalent interactions, leading to loss of enzymatic activity. Spectroscopic analysis shows secondary and tertiary structure perturbation upon aggregation. MALDI-TOF mass spectrometry of LysC peptides reveals UV-induced chemical modifications to Trp, Met, and Cys residues, but the conserved active-site Cys remains intact after UV exposure that completely inactivates the enzyme, indicating that UV-induced inactivation results from aggregation/structural changes rather than direct active-site damage.\",\n      \"method\": \"UV irradiation of purified recombinant ALDH3A1; enzyme activity assay, spectroscopy (secondary/tertiary structure), MALDI-TOF mass spectrometry peptide mapping\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical reconstitution with purified protein, multiple orthogonal structural and chemical methods including mass spectrometry, single lab\",\n      \"pmids\": [\"21203538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ALDH3A1 overexpression in rabbit corneal keratocytes (TRK43) protects cells from 4-HNE toxicity by: metabolizing 4-HNE and its glutathione conjugate, preventing 4-HNE-protein adduct formation, preventing apoptosis, maintaining glutathione homeostasis, and preserving proteasome function.\",\n      \"method\": \"Stable transfection; cell viability, morphology, Western blot for 4-HNE adducts, apoptosis assay, GSH measurement, proteasome activity assay\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean gain-of-function with six orthogonal cellular/biochemical readouts, single lab\",\n      \"pmids\": [\"22406320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A selective submicromolar ALDH3A1 inhibitor, CB7 (1-[(4-fluorophenyl)sulfonyl]-2-methyl-1H-benzimidazole; IC50 0.2 µM), binds within the aldehyde substrate-binding pocket of ALDH3A1, as established by structural crystallography, kinetics, and mutagenesis. CB7 does not inhibit ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, or ALDH2. Sensitization of ALDH3A1-expressing lung adenocarcinoma (A549) and glioblastoma (SF767) cells to mafosfamide occurs in the presence of CB7, while primary lung fibroblasts lacking ALDH3A1 are unaffected.\",\n      \"method\": \"X-ray crystallography (structure of inhibitor-bound ALDH3A1), enzyme kinetics, site-directed mutagenesis, cell proliferation assay\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure, in vitro enzyme kinetics, mutagenesis, and cellular functional validation; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"24387105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A selective ALDH3A1 inhibitor, CB29, binds within the aldehyde substrate-binding site of ALDH3A1 as shown by kinetics and crystallography, and enhances mafosfamide sensitivity in ALDH3A1-expressing A549 and SF767 tumor cells but not in ALDH3A1-negative CCD-13Lu fibroblasts. CB29 does not inhibit ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, or ALDH2 at up to 250 µM.\",\n      \"method\": \"X-ray crystallography, enzyme kinetics, cell proliferation assay\",\n      \"journal\": \"Chembiochem : a European journal of chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure of inhibitor-bound enzyme, kinetics, and cellular validation across matched ALDH3A1-positive and -negative lines; multiple orthogonal methods\",\n      \"pmids\": [\"24677340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The Aldh3a1 gene is regulated by the aromatic hydrocarbon receptor (AhR): at least four functional aromatic hydrocarbon response elements (AHREs) in the 5' flanking region act cooperatively to mediate dioxin (TCDD)-induced upregulation. A putative negative regulatory element (NRE) controls basal expression independently of dioxin inducibility. TCDD-mediated upregulation in Hepa-1c1c7 cells depends exclusively on the AhR.\",\n      \"method\": \"Deletion reporter gene constructs (CAT/luciferase) transiently transfected in mouse hepatoma cells; genomic cloning and sequencing; AhR-dependence assessed with AhR-deficient mutant cells\",\n      \"journal\": \"Pharmacogenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — promoter deletion/reporter assay with functional AhR requirement validation, multiple constructs, single lab\",\n      \"pmids\": [\"10591537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The Aldh3a1c allele in SWR/J mice encodes a low-activity ALDH3A1 variant due to four amino acid substitutions (G88R, I154N, H305R, I352V). The I154N disrupts a potential alpha-helix in the Rossmann fold; H305R affects a beta-strand and likely directly impacts catalytic activity. Loss of ALDH3A1 activity in SWR/J mice is associated with extensive corneal clouding after UV exposure.\",\n      \"method\": \"RT-PCR and sequencing of cDNA; enzyme activity assay; comparison of allelic variants across inbred strains; UV challenge in vivo\",\n      \"journal\": \"Pharmacogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — sequence-activity correlation with enzymatic validation, multiple strains, in vivo phenotype; single lab, no site-directed mutagenesis confirmation\",\n      \"pmids\": [\"10376761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"UVB radiation at ≥0.2 J/cm2 reduces corneal ALDH3A1 mRNA and protein levels (~80%) and enzymatic activity in C57BL/6J mice (transcriptional and/or post-translational downregulation). Lower doses (0.05–0.1 J/cm2) reduce enzymatic activity without altering mRNA or protein, indicating post-translational modification. In vitro experiments with purified recombinant ALDH3A1 show that UVR causes both covalent and non-covalent protein aggregation without detectable precipitation.\",\n      \"method\": \"Northern blot, Western blot, enzyme activity assay in mouse corneas; in vitro aggregation assay with purified recombinant ALDH3A1; dose-response UV exposure\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo dose-response with multiple molecular readouts plus in vitro protein aggregation assay; single lab\",\n      \"pmids\": [\"12604188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A small molecule, Alda-89, enables ALDH3A1 to metabolize acetaldehyde—a substrate it normally does not efficiently process. In vivo, Alda-89 combined with the ALDH2 activator Alda-1 reduces blood ethanol and acetaldehyde levels and decreases acetaldehyde-induced behavioral impairment in both wild-type and ALDH2*1/*2 heterozygous knock-in mice after acute ethanol intoxication.\",\n      \"method\": \"Pharmacological activation with small molecule (Alda-89); blood ethanol/acetaldehyde measurement; behavioral assay in wild-type and ALDH2*2 knock-in mice\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo pharmacological recruitment with biochemical (blood metabolite) and behavioral readouts, tested in two genotypes, published in PNAS\",\n      \"pmids\": [\"25713355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ALDH3A1 decreases corneal epithelial cell proliferation through both enzymatic and non-enzymatic mechanisms. Inducible expression of wild-type (wt) but not catalytically-inactive (mu) ALDH3A1 promotes nuclear sequestration of tumor suppressor p53. In vivo, augmented proliferation is seen only in Aldh1a1/Aldh3a1 double-knockout mice (not Aldh3a1 single KO), and these hyper-proliferative corneas show near-complete loss of p53 expression. ALDH3A1 expression also modulates corneal differentiation markers.\",\n      \"method\": \"Tet-On inducible cell line expressing wt or catalytically-inactive ALDH3A1; BrdU proliferation assay; p53 nuclear localization by immunofluorescence; Aldh1a1/Aldh3a1 double-KO mouse cornea phenotyping; differentiation marker mRNA analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — catalytic mutant vs. wt comparison establishes enzymatic vs. non-enzymatic contributions, p53 localization mechanistically linked, validated in vivo with double-KO epistasis\",\n      \"pmids\": [\"26751691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Recombinant human ALDH3A1 exhibits molecular chaperone-like activity in vitro, protecting SmaI restriction enzyme and citrate synthase from thermal stress-induced precipitation and inactivation. Overexpression of ALDH3A1 in E. coli confers resistance to thermal shock. ALDH3A1 overexpression in human corneal HCE-2 cells protects against H2O2- and tert-butyl hydroperoxide-induced cytotoxicity.\",\n      \"method\": \"In vitro chaperone assay with purified recombinant ALDH3A1 and model substrates (thermal aggregation assay); bacterial thermal shock survival; cell viability assay in HCE-2 cells\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro reconstitution of chaperone function with two model substrates plus cellular validation, single lab\",\n      \"pmids\": [\"28526614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Activity-based protein profiling (chemoproteomics) identified the catalytic cysteine of ALDH3A1 as the primary cellular target of covalent ligand DKM 3-42, which impairs lung cancer cell survival. A more potent and selective lead covalent inhibitor EN40, identified through direct ALDH3A1-targeted chemoproteomic screening, inhibits ALDH3A1 activity and impairs lung cancer pathogenicity both in situ and in vivo.\",\n      \"method\": \"Activity-based protein profiling (ABPP); covalent ligand library screen; in vitro ALDH3A1 activity assay; lung cancer cell viability and tumor xenograft (in vivo)\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — chemoproteomic target identification, enzymatic activity confirmation, in vitro and in vivo tumor models, multiple orthogonal methods\",\n      \"pmids\": [\"30004670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Pharmacological inhibition of the Wnt pathway (porcupine inhibitor LGK974) synergistically suppresses glioma cell growth with temozolomide; transcriptomic analysis revealed ALDH3A1 expression is significantly downregulated by this combination. Knockdown of ALDH3A1 alone increases TMZ efficacy and reduces clonogenic potential, indicating that Wnt signaling-mediated chemoresistance is at least partly mediated through ALDH3A1.\",\n      \"method\": \"Porcupine inhibitor treatment, TMZ combination; transcriptomic analysis; ALDH3A1 siRNA knockdown; clonogenic assay; stem cell marker expression\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pathway epistasis by pharmacological inhibition and siRNA KD; single lab; no direct biochemical interaction assay\",\n      \"pmids\": [\"29854309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FBXL12, an F-box protein forming an SCF ubiquitin E3 ligase, interacts specifically with members of the ALDH3 family and mediates their polyubiquitylation, leading to proteasomal degradation. FBXL12 deficiency causes ALDH3 accumulation in placenta and impairs trophoblast stem cell differentiation. Forced expression of ALDH3 in wild-type trophoblast stem cells phenocopies the FBXL12-deficient differentiation defect; inhibition of ALDH3 activity by gossypol rescues the phenotype of FBXL12 deficiency.\",\n      \"method\": \"Co-immunoprecipitation (FBXL12-ALDH3 interaction); polyubiquitylation assay; FBXL12 knockout mice; forced ALDH3 overexpression in TSCs; gossypol pharmacological rescue\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ubiquitylation assay, KO mouse, gain-of-function rescue experiment, and pharmacological rescue; multiple orthogonal methods establishing mechanism\",\n      \"pmids\": [\"26124079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Mutation of the circadian clock component Per2 in oncogene-transformed mouse embryonic fibroblasts leads to ~7-fold elevated ALDH3A1 protein levels compared to wild-type oncogene-transformed cells. Elevated ALDH3A1 prevents chemotherapeutic drug-induced accumulation of reactive oxygen species, conferring resistance to methotrexate, gemcitabine, etoposide, vincristine, and oxaliplatin. shRNA-mediated suppression of Aldh3a1 relieves this chemoresistance.\",\n      \"method\": \"Per2-mutant mouse embryonic fibroblasts; Western blot for ALDH3A1; ROS measurement; cell viability with chemotherapy agents; shRNA knockdown of Aldh3a1\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — genetic epistasis via KD rescue, ROS mechanistic readout, single lab; pathway placement via PER2/ALDH3A1 axis\",\n      \"pmids\": [\"30429219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Arachidonic acid-induced growth suppression of A549 lung tumor cells is associated with reduced ALDH3A1 enzymatic activity, protein, and mRNA levels and increased lipid peroxidation. Activation of PPARγ mediates this downregulation; blockade of PPARγ with antagonist GW9662 prevents the arachidonic acid-mediated reduction of ALDH3A1 expression and the growth inhibition. PPARγ activation and ALDH3A1 reduction are also prevented by vitamin E co-treatment.\",\n      \"method\": \"Arachidonic acid treatment of A549 cells; PPARγ antagonist (GW9662) pharmacological blockade; vitamin E co-treatment; ALDH3A1 enzyme activity, protein, and mRNA measurement; NF-κB binding assay\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological epistasis (PPARγ blockade rescues ALDH3A1 expression); multiple corroborating readouts; single lab\",\n      \"pmids\": [\"16716894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In aldh3a1-/- zebrafish larvae generated by CRISPR-Cas9, 4-HNE (but not methylglyoxal) accumulates, demonstrating that Aldh3a1 is the primary detoxifier of 4-HNE in vivo. 4-HNE accumulation disrupts pancreas morphology, impairs glucose homeostasis, and causes retinal vasodilatory alterations. The retinal and hyperglycemic phenotype can be rescued by L-Carnosine treatment.\",\n      \"method\": \"CRISPR-Cas9 knockout zebrafish; reactive carbonyl species measurement; glucose measurement; zebrafish transgenic reporter lines for vasculature and pancreas; transcriptomics; metabolomics; ALDH activity assay; pdx1 silencing epistasis\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function in vivo (CRISPR KO zebrafish), substrate identification by metabolomics, multiple phenotypic readouts, pharmacological rescue\",\n      \"pmids\": [\"32980661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In NSCLC, hypoxia induces ALDH3A1 expression via the AHR/ARNT pathway; ALDH3A1 promotes cell proliferation by enhancing glycolysis and suppressing OXPHOS through activation of the HIF-1α/LDHA pathway. β-elemene downregulates ALDH3A1, inhibiting glycolysis and enhancing OXPHOS to suppress NSCLC proliferation in vitro and in vivo.\",\n      \"method\": \"Hypoxia cell treatment; ALDH3A1 knockdown/overexpression; glycolysis and OXPHOS measurement; HIF-1α/LDHA pathway Western blot; β-elemene treatment; xenograft mouse model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — cellular gain/loss-of-function with pathway marker readouts and in vivo xenograft; single lab; mechanism placement via HIF-1α/LDHA\",\n      \"pmids\": [\"37730658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"EN40 (covalent ALDH3A1 inhibitor targeting the catalytic cysteine) significantly enhances ferroptosis sensitivity in squamous cell carcinoma cells by its enzymatic activity-dependent inhibition of aldehyde catabolism and mitigation of lipid peroxidation. High ALDH3A1 expression in SCC is transcriptionally governed by TP63, which binds to a super-enhancer of ALDH3A1. The combination of EN40 and a ferroptosis inducer synergistically inhibits SCC proliferation in vitro and tumor growth in vivo.\",\n      \"method\": \"Covalent inhibitor (EN40) treatment; ferroptosis assay; lipid peroxidation measurement; ALDH3A1 overexpression/knockdown; ChIP-seq for TP63 binding to ALDH3A1 super-enhancer; SCC organoid and xenograft models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — enzymatic mechanism validated with covalent inhibitor and genetic controls, transcriptional regulation by TP63 via ChIP, multiple in vitro and in vivo models\",\n      \"pmids\": [\"39863749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Mechanical strain (3%) applied to human keratocytes upregulates ALDH3A1 expression, which suppresses NF-κB nuclear translocation and reduces keratocyte proliferation and migration. ALDH3A1 knockdown promotes NF-κB nuclear translocation and enhances proliferation and migration. Elevated ALDH3A1 is also observed in mouse corneal injury models and in keratoconus patient keratocytes.\",\n      \"method\": \"Flexcell Tension System (3% strain); RT-qPCR and Western blot for ALDH3A1; RNAi knockdown; NF-κB nuclear translocation by immunofluorescence; BrdU proliferation and scratch wound healing assay; mouse injury model; single-cell RNA-seq of keratoconus patient keratocytes\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — KD with defined phenotypic readouts (proliferation, migration, NF-κB localization), in vivo confirmation, single lab\",\n      \"pmids\": [\"39652089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"Human ALDH3 (ALDH3A1) gene is assigned to chromosome 17 using human-rodent hybrid cells. The enzyme shows optimal activity with benzaldehyde and can utilize either NAD or NADP as cofactor. It is expressed at highest levels in lung and stomach, with no expression in fetal tissues, blood, hair roots, or fibroblasts.\",\n      \"method\": \"Human-rodent somatic cell hybrids; enzyme activity assay; antiserum immunoprecipitation; chromosome assignment\",\n      \"journal\": \"Annals of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chromosomal assignment by somatic cell hybrid panel, biochemical cofactor specificity by enzyme assay; foundational characterization study\",\n      \"pmids\": [\"4073832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Bos taurus ALDH3A1 exhibits unprecedented turnover with the non-canonical redox cofactor nicotinamide mononucleotide (NMN+), with kcat values matching or exceeding that of NAD+. A conserved RH/QxxR sequence motif in ALDH3A1 reinforces cofactor positioning and pre-organizes the active site without dependence on the adenosine monophosphate moiety of NAD+. Structural and dynamic analyses support this mechanism.\",\n      \"method\": \"In vitro enzyme kinetics (NMN+ and NAD+ comparison); structural analysis; sequence motif analysis; introduction of RH/QxxR motif into other ALDH scaffolds\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution with kinetics and structural analysis; preprint, single lab, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.08.01.668186\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Dietary isothiocyanates (ITCs), specifically allyl-isothiocyanate, form a covalent adduct with the catalytic Cys243 residue of salivary ALDH3A1, causing irreversible inhibition. This inhibition, confirmed by X-ray crystallography and mass spectrometry, disrupts metabolic conversion of odorant aldehydes in saliva, modulating aroma release as confirmed by GC-MS.\",\n      \"method\": \"Enzymology (in vitro inhibition kinetics); X-ray crystallography of ITC-ALDH3A1 adduct; mass spectrometry; GC-MS analysis of odorant metabolites; ex vivo saliva assay\",\n      \"journal\": \"Food chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure identifying Cys243 as covalent adduct site, mass spectrometry confirmation, functional odorant release assay; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"41672019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ALDH3A1 expression is constitutively elevated in stable MCF-7 breast cancer sublines due to constitutively upregulated transcription driven by transactivated electrophile responsive elements (EpREs) in the 5'-upstream region of the ALDH3A1 gene. Elevated ALDH3A1 mRNA is not due to gene amplification, DNA hypomethylation, or mRNA stabilization, pointing to altered EpRE signaling as the mechanism.\",\n      \"method\": \"RT-PCR for ALDH3A1 mRNA; Southern blot for gene amplification; methylation analysis; mRNA stability assay; comparison of MCF-7 sublines selected with oxazaphosphorines or polycyclic aromatic hydrocarbons\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — mechanistic exclusion of alternative mechanisms (amplification, methylation, mRNA stability) by direct assay; single lab; pathway placement via EpRE\",\n      \"pmids\": [\"11306049\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ALDH3A1 is a cytosolic NAD(P)+-dependent aldehyde dehydrogenase that preferentially oxidizes medium-chain (≥6 carbon) aliphatic and hydroxy-alkenyl aldehydes, especially 4-hydroxy-2-nonenal (4-HNE) generated during lipid peroxidation, to their corresponding carboxylic acids; it is abundantly expressed in the mammalian cornea (where it functions as a 'corneal crystallin' protecting against UV-induced oxidative damage via aldehyde detoxification, NADPH generation, direct UV absorption, and chaperone-like protein protection), is inducibly regulated by the aryl hydrocarbon receptor (AhR) through aromatic hydrocarbon response elements and by NRF2/EpRE signaling, is targeted for proteasomal degradation by the SCF-FBXL12 E3 ligase (controlling trophoblast differentiation), harbors a catalytic Cys243 that is the target of covalent inhibitors and isothiocyanate adducts, modulates corneal epithelial homeostasis by promoting nuclear p53 sequestration to restrict proliferation, and confers cancer chemoresistance and ferroptosis resistance through enzymatic detoxification of toxic aldehydes including oxazaphosphorine metabolites, with transcription in squamous cancers governed by TP63 binding to a super-enhancer.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ALDH3A1 is a cytosolic NAD(P)+-dependent aldehyde dehydrogenase that detoxifies medium-chain (≥6 carbon) aliphatic and hydroxy-alkenyl aldehydes, most notably the lipid-peroxidation product 4-hydroxy-2-nonenal (4-HNE), oxidizing them to non-toxic carboxylic acids while short-chain aldehydes are poor substrates [#0, #1]. Through this activity it protects cells from oxidative and UV-induced injury: it prevents 4-HNE-protein adduct formation, preserves glutathione homeostasis and proteasome function, and blocks caspase-3/PARP-mediated apoptosis in corneal and other cells [#2, #3, #7]. In vivo, Aldh3a1-null mice develop cataracts and accumulate 4-HNE/malondialdehyde adducts, and CRISPR knockout zebrafish establish ALDH3A1 as the primary 4-HNE detoxifier whose loss disrupts glucose homeostasis and ocular vasculature [#5, #21]. Beyond catalysis, the abundant corneal protein protects co-incubated enzymes by directly absorbing UV energy and exhibits molecular chaperone-like activity against thermal aggregation, acting as a multifunctional 'corneal crystallin' [#4, #15]. ALDH3A1 also restrains corneal epithelial proliferation through both enzymatic and non-enzymatic routes, promoting nuclear sequestration of p53 and suppressing NF-κB nuclear translocation [#14, #24]. Catalysis depends on an active-site Cys243 that is the covalent target of selective inhibitors and dietary isothiocyanate adducts, and selective substrate-pocket inhibitors (CB7, CB29, EN40) confirm a druggable aldehyde-binding site [#8, #9, #16, #27]. Expression is transcriptionally induced by the aryl hydrocarbon receptor via aromatic hydrocarbon response elements and by electrophile-responsive element signaling, and the SCF-FBXL12 E3 ligase targets ALDH3 proteins for proteasomal degradation to control trophoblast differentiation [#10, #28, #18]. In cancer, ALDH3A1 confers chemoresistance and ferroptosis resistance by detoxifying toxic aldehydes and limiting lipid peroxidation, with high expression in squamous carcinoma driven by TP63 binding to a super-enhancer [#19, #23, #16].\",\n  \"teleology\": [\n    {\n      \"year\": 1985,\n      \"claim\": \"Established the basic identity of the human enzyme—its chromosomal locus, dual NAD/NADP cofactor usage, and tissue distribution—providing the foundation for all later mechanistic work.\",\n      \"evidence\": \"Human-rodent somatic cell hybrids, enzyme activity assays, and antiserum immunoprecipitation\",\n      \"pmids\": [\"4073832\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not define physiological substrate preference\", \"No structural or active-site information\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined how ALDH3A1 transcription is controlled, showing the gene is an AhR target driven by cooperative aromatic hydrocarbon response elements and that natural low-activity alleles arise from coding substitutions affecting the Rossmann fold and catalysis.\",\n      \"evidence\": \"Promoter deletion/reporter assays in AhR-deficient hepatoma cells; allelic cDNA sequencing and enzyme activity across inbred mouse strains with UV challenge\",\n      \"pmids\": [\"10591537\", \"10376761\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No site-directed mutagenesis confirmation of the allelic substitutions\", \"Negative regulatory element factor not identified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated the protective cellular function: ALDH3A1 oxidizes medium-chain aldehydes to confer resistance to aldehyde toxicity, distinguishing it from ALDH1A1, and linked its overexpression in cancer cells to EpRE-driven transcription.\",\n      \"evidence\": \"Stable transfection of V79 cells with viability/GSH/apoptosis/adduct readouts; RT-PCR and exclusion assays in MCF-7 oxazaphosphorine-resistant sublines\",\n      \"pmids\": [\"11306050\", \"11306049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"EpRE transactivating factor not directly identified\", \"Did not address in vivo relevance\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Quantified substrate specificity with purified recombinant enzyme and localized ALDH3A1 to corneal epithelium and keratocytes, while showing it protects corneal cells against UV- and 4-HNE-induced apoptosis with measurable kinetics.\",\n      \"evidence\": \"Recombinant Sf9 protein with kinetics and immunohistochemistry; stable transfection of HCE cells with caspase-3/PARP/NAD(P)H readouts; mouse corneal UV dose-response\",\n      \"pmids\": [\"12943535\", \"12706498\", \"12604188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"UV downregulation mechanism (transcriptional vs post-translational) only partly resolved\", \"No structural model of substrate binding\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed that ALDH3A1 is multifunctional—protecting other proteins both enzymatically (aldehyde clearance preserving G6PDH) and non-enzymatically by direct UV absorption—and that its downregulation by PPARγ underlies arachidonic-acid-induced tumor growth suppression.\",\n      \"evidence\": \"Co-incubation of purified ALDH3A1 with G6PDH under UVB/aldehyde stress; stable transfection of rabbit corneal fibroblasts; PPARγ antagonist epistasis in A549 cells\",\n      \"pmids\": [\"17158879\", \"17023273\", \"16716894\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of the chaperone-like structural transition not defined\", \"Direct PPARγ binding to the gene not shown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Provided in vivo genetic proof that corneal ALDH3A1 protects the eye against oxidative damage, with knockout mice developing cataracts and accumulating aldehyde-protein adducts, partly redundant with lens ALDH1A1.\",\n      \"evidence\": \"Single and double Aldh1a1/Aldh3a1 knockout mice with ocular phenotyping, proteasome and adduct assays, and UVB challenge\",\n      \"pmids\": [\"17567582\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of enzymatic vs UV-filtering function not separated genetically\", \"Mechanism of cataractogenesis downstream of adducts unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed that UV inactivation of ALDH3A1 results from aggregation and structural perturbation rather than direct active-site damage, since the catalytic cysteine remains intact in fully inactivated enzyme.\",\n      \"evidence\": \"UV irradiation of purified recombinant ALDH3A1 with activity assays, spectroscopy, and MALDI-TOF peptide mapping\",\n      \"pmids\": [\"21203538\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Aggregation interface not mapped\", \"In vivo relevance of these specific modifications not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Consolidated the corneal protective mechanism, showing ALDH3A1 metabolizes 4-HNE and its glutathione conjugate while preserving proteasome function and GSH homeostasis.\",\n      \"evidence\": \"Stable transfection of rabbit keratocytes with six orthogonal cellular and biochemical readouts\",\n      \"pmids\": [\"22406320\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single cell system\", \"Did not address downstream signaling consequences\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined a druggable aldehyde substrate-binding pocket by crystallizing selective small-molecule inhibitors (CB7, CB29) and validated that their inhibition sensitizes ALDH3A1-positive tumor cells to oxazaphosphorine chemotherapy.\",\n      \"evidence\": \"X-ray crystallography of inhibitor-bound ALDH3A1, enzyme kinetics, mutagenesis, and matched ALDH3A1-positive/negative cell proliferation assays\",\n      \"pmids\": [\"24387105\", \"24677340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibitor potency in vivo not established in these studies\", \"Selectivity against full ALDH family not exhaustively profiled\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated mechanistic plasticity—both substrate scope (small molecule Alda-89 enabling acetaldehyde metabolism in vivo) and a free-standing molecular chaperone activity protecting model substrates from thermal aggregation—and clarified its FBXL12-dependent turnover controlling trophoblast differentiation.\",\n      \"evidence\": \"Pharmacological activation with Alda-89 and blood metabolite/behavioral assays in mice; in vitro chaperone assays with citrate synthase/SmaI; reciprocal Co-IP, ubiquitylation assay, FBXL12 knockout mice, and gossypol rescue\",\n      \"pmids\": [\"25713355\", \"28526614\", \"26124079\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of chaperone activity unresolved\", \"FBXL12 specificity within ALDH3 family not fully dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Separated enzymatic from non-enzymatic roles in corneal homeostasis, showing only catalytically active ALDH3A1 drives nuclear p53 sequestration to restrict epithelial proliferation, validated by double-knockout epistasis.\",\n      \"evidence\": \"Tet-On inducible wt vs catalytically-inactive ALDH3A1 cells, BrdU and p53 immunofluorescence, and Aldh1a1/Aldh3a1 double-KO mouse cornea phenotyping\",\n      \"pmids\": [\"26751691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link between catalysis and p53 trafficking not defined\", \"Differentiation marker control mechanism unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established ALDH3A1 as a cancer chemoresistance and survival factor across contexts—covalent active-site inhibition (DKM 3-42, EN40) impairs lung cancer pathogenicity, Wnt and PER2 circadian signaling converge on ALDH3A1 to drive resistance via ROS detoxification.\",\n      \"evidence\": \"Activity-based protein profiling and covalent inhibitors with lung cancer xenografts; porcupine inhibitor/TMZ epistasis with siRNA in glioma; Per2-mutant fibroblasts with shRNA and ROS readouts\",\n      \"pmids\": [\"30004670\", \"29854309\", \"30429219\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct regulatory links between Wnt/PER2 and the ALDH3A1 promoter not shown\", \"Single-lab pathway placements\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Confirmed in a third species (zebrafish) that ALDH3A1 is the principal in vivo 4-HNE detoxifier, with loss causing 4-HNE accumulation, hyperglycemia, and retinal vascular changes rescuable by L-carnosine.\",\n      \"evidence\": \"CRISPR-Cas9 knockout zebrafish with reactive carbonyl metabolomics, glucose measurement, transgenic vascular/pancreas reporters, and pharmacological rescue\",\n      \"pmids\": [\"32980661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking 4-HNE to pancreatic/retinal phenotypes not fully resolved\", \"Mammalian metabolic relevance inferred not demonstrated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended the cancer role to metabolic reprogramming, showing hypoxia-induced ALDH3A1 (via AHR/ARNT) promotes glycolysis and suppresses OXPHOS through the HIF-1α/LDHA axis to drive NSCLC proliferation.\",\n      \"evidence\": \"Hypoxia treatment, ALDH3A1 knockdown/overexpression, glycolysis/OXPHOS assays, pathway Western blots, and xenografts\",\n      \"pmids\": [\"37730658\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism linking aldehyde dehydrogenase activity to HIF-1α/LDHA not established\", \"Single-lab pathway placement\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined the transcriptional control and therapeutic exploitation of ALDH3A1 in squamous carcinoma—TP63 drives high expression via a super-enhancer, and covalent inhibition (EN40) enzyme-dependently sensitizes cells to ferroptosis—and uncovered a Cys243-targeting dietary isothiocyanate adduct modulating odorant aldehyde metabolism, plus non-canonical NMN+ cofactor usage.\",\n      \"evidence\": \"ChIP-seq of TP63, covalent EN40 with ferroptosis/lipid peroxidation assays and SCC organoids/xenografts; crystallography and mass spectrometry of ITC-Cys243 adducts with GC-MS; in vitro kinetics with NMN+ (preprint)\",\n      \"pmids\": [\"39863749\", \"41672019\", \"bio_10.1101_2025.08.01.668186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of NMN+ cofactor usage not established (preprint)\", \"Generality of TP63 regulation across SCC subtypes not fully tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the non-enzymatic functions (UV absorption, chaperone activity, p53 sequestration) are mechanistically coordinated with catalytic aldehyde clearance, and whether targeting ALDH3A1 in cancer can be achieved without compromising its protective corneal/ocular roles, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model linking catalysis to chaperone/UV-filtering functions\", \"Tissue-selective therapeutic window not defined\", \"Direct molecular partners mediating p53 and NF-κB effects unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 2, 21, 25]},\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [4, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [2, 3, 5, 21]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [16, 19, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FBXL12\",\n      \"TP63\",\n      \"p53\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}